StemCells, Inc. Announces Strategic Realignment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. SPOT
6. BYD
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to StemCells, Inc. Announces Strategic Realignment

StemCells (STEM) PT Cut to $3 at Maxim Group

December 23, 2015 12:18 PM EST

Maxim Group analyst Jason Kolbert lowered his price target on StemCells (NASDAQ: STEM) to $3.00 (from $5.00) but maintained a Buy rating after the company suspended the phase II AMD (Radiant) study to focus on the spinal cord injury (SCI) trial.

Stem's management announced the decision to focus on the spinal cord injury (SCI) trial. Management will suspend the company's phase II AMD (Radiant)... More

UPDATE: StemCells (STEM) Declines After Shares Resume Trading

December 23, 2015 8:10 AM EST

(Updated - December 23, 2015 8:16 AM EST)

StemCells (NASDAQ: STEM) Declines After Shares Resume Trading

... More